Study of Efficacy, Safety and Tolerability of DFV890 in Patients With Knee Osteoarthritis

Summary

This was a double-blinded, two-arm, phase 2a study to assess efficacy, safety and tolerability of DFV890 in participants with symptomatic knee osteoarthritis.

Timeline

Start

2021-09-20

Primary completion

2024-12-14

Completion

2024-12-23

Outcome

Missed primary endpoint

registry analysis (other test); DFV890 vs Placebo; p = 0.0872; Mean Difference (Net) 4.9806 (95% CI -2.2 to 12.2); Mixed effects model for repeated measure NCT04886258 ↗

Drugs

Indications